Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.56 |
| ▸ | MEN1 | O00255 | 5/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 2/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6280252 | 0.78 | MEN1 (0.67) | NPSR1KMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL24210094 | 0.76 | NPSR1 (1.00) | NPSR1KMT2AMEN1TDP1ALDH1A1 | |
| SCHEMBL6346019 | 0.76 | KMT2A (0.76) | NPSR1KMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL6277413 | 0.76 | CYP1A2 (0.67) | NPSR1KMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL6277599 | 0.75 | ALDH1A1 (0.65) | NPSR1KMT2AMEN1TDP1LMNA | |
| SCHEMBL24210097 | 0.74 | NPSR1 (0.59) | NPSR1KMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL6281550 | 0.74 | KMT2A (0.86) | NPSR1KMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL6279510 | 0.73 | KMT2A (0.73) | NPSR1KMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL6280499 | 0.73 | ALDH1A1 (0.76) | NPSR1KMT2AMEN1TDP1LMNA | |
| SCHEMBL1611034 | 0.73 | KMT2A (0.56) | NPSR1KMT2AMEN1TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569919-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2012-04-18 | — | — | EP | disclosed |
| US-7642277-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-05 | — | — | US | disclosed |
| US-20050054639-A1 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054639-A1 | Non-nucleoside reverse transcriptase inhibitors | NAT1, SUB1, RTF2 | NPSR1 3623/4885KMT2A 895/4885MEN1 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.